Drug-Induced Hepatotoxicity: Metabolic, Genetic and Immunological Basis
Abstract
:1. Introduction
2. Metabolic Basis of Drug-Induced Hepatotoxicity
3. Genetic Basis of Drug-Induced Hepatotoxicity
4. Immune Basis of Drug Hepatotoxicity
5. Conclusions
Acknowledgments
Conflicts of Interest
References
- Schiodt, F.V.; Atillasoy, E.; Shakil, A.O.; Schiff, E.R.; Caldwell, C.; Kowdley, K.V.; Stribling, R.; Crippin, J.S.; Flamm, S.; Somberg, K.A.; et al. Etiology and outcome for 295 patients with acute liver failure in the United States. Liver Transpl. Surg 1999, 5, 29–34. [Google Scholar]
- Temple, R.J.; Himmel, M.H. Safety of newly approved drugs: Implications for prescribing. JAMA 2002, 287, 2273–2275. [Google Scholar]
- Ostapowicz, G.; Fontana, R.J.; Schiodt, F.V.; Larson, A.; Davern, T.J.; Han, S.H.; McCashland, T.M.; Shakil, A.O.; Hay, J.E.; Hynan, L.; et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann. Intern. Med 2002, 137, 947–954. [Google Scholar]
- Lee, W.M.; Senior, J.R. Recognizing drug-induced liver injury: Current problems, possible solutions. Toxicol. Pathol 2005, 33, 155–164. [Google Scholar]
- Tujios, S.; Fontana, R.J. Mechanisms of drug-induced liver injury: From bedside to bench. Nat. Rev. Gastroenterol. Hepatol 2011, 8, 202–211. [Google Scholar]
- Garcia-Cortes, M.; Stephens, C.; Lucena, M.I.; Fernandez-Castaner, A.; Andrade, R.J. Causality assessment methods in drug induced liver injury: Strengths and weaknesses. J. Hepatol 2011, 55, 683–691. [Google Scholar]
- Lee, W.M. Drug-induced hepatotoxicity. N. Engl. J. Med 2003, 349, 474–485. [Google Scholar]
- Cohen, S.D.; Pumford, N.R.; Khairallah, E.A.; Boekelheide, K.; Pohl, L.R.; Amouzadeh, H.R.; Hinson, J.A. Selective protein covalent binding and target organ toxicity. Toxicol. Appl. Pharmacol 1997, 143, 1–12. [Google Scholar]
- Jaeschke, H.; Knight, T.R.; Bajt, M.L. The role of oxidant stress and reactive nitrogen species in acetaminophen hepatotoxicity. Toxicol. Lett 2003, 144, 279–288. [Google Scholar]
- Jaeschke, H.; Bajt, M.L. Intracellular signaling mechanisms of acetaminophen-induced liver cell death. Toxicol. Sci 2006, 89, 31–41. [Google Scholar]
- Jaeschke, H.; McGill, M.R.; Ramachandran, A. Oxidant stress, mitochondria, and cell death mechanisms in drug-induced liver injury: Lessons learned from acetaminophen hepatotoxicity. Drug Metab. Rev 2012, 44, 88–106. [Google Scholar]
- Boelsterli, U.A. Diclofenac-induced liver injury: A paradigm of idiosyncratic drug toxicity. Toxicol. Appl. Pharmacol 2003, 192, 307–322. [Google Scholar]
- Roth, R.A.; Harkema, J.R.; Pestka, J.P.; Ganey, P.E. Is exposure to bacterial endotoxin a determinant of susceptibility to intoxication from xenobiotic agents? Toxicol. Appl. Pharmacol 1997, 147, 300–311. [Google Scholar]
- Buchweitz, J.P.; Ganey, P.E.; Bursian, S.J.; Roth, R.A. Underlying endotoxemia augments toxic responses to chlorpromazine: Is there a relationship to drug idiosyncrasy? J. Pharmacol. Exp. Ther 2002, 300, 460–467. [Google Scholar]
- Deng, X.; Stachlewitz, R.F.; Liguori, M.J.; Blomme, E.A.; Waring, J.F.; Luyendyk, J.P.; Maddox, J.F.; Ganey, P.E.; Roth, R.A. Modest inflammation enhances diclofenac hepatotoxicity in rats: Role of neutrophils and bacterial translocation. J. Pharmacol. Exp. Ther 2006, 319, 1191–1199. [Google Scholar]
- Lu, J.; Jones, A.D.; Harkema, J.R.; Roth, R.A.; Ganey, P.E. Amiodarone exposure during modest inflammation induces idiosyncrasy-like liver injury in rats: Role of tumor necrosis factor-alpha. Toxicol. Sci 2012, 125, 126–133. [Google Scholar]
- Luyendyk, J.P.; Maddox, J.F.; Cosma, G.N.; Ganey, P.E.; Cockerell, G.L.; Roth, R.A. Ranitidine treatment during a modest inflammatory response precipitates idiosyncrasy-like liver injury in rats. J. Pharmacol. Exp. Ther 2003, 307, 9–16. [Google Scholar]
- Dugan, C.M.; MacDonald, A.E.; Roth, R.A.; Ganey, P.E. A mouse model of severe halothane hepatitis based on human risk factors. J. Pharmacol. Exp. Ther 2010, 333, 364–372. [Google Scholar]
- Pohl, L.R.; Satoh, H.; Christ, D.D.; Kenna, J.G. The immunologic and metabolic basis of drug hypersensitivities. Annu. Rev. Pharmacol. Toxicol 1988, 28, 367–387. [Google Scholar]
- Donaldson, P.T.; Daly, A.K.; Henderson, J.; Graham, J.; Pirmohamed, M.; Bernal, W.; Day, C.P.; Aithal, G.P. Human leucocyte antigen class II genotype in susceptibility and resistance to co-amoxiclav-induced liver injury. J. Hepatol 2010, 53, 1049–1053. [Google Scholar]
- Daly, A.K.; Donaldson, P.T.; Bhatnagar, P.; Shen, Y.; Peer, I.; Floratos, A.; Daly, M.J.; Goldstein, D.B.; John, S.; Nelson, M.R.; et al. HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat. Genet 2009, 41, 816–819. [Google Scholar]
- Daly, A.K. Genetic polymorphisms affecting drug metabolism: Recent advances and clinical aspects. Adv. Pharmacol 2012, 63, 137–167. [Google Scholar]
- Huang, Y.S.; Chern, H.D.; Su, W.J.; Wu, J.C.; Chang, S.C.; Chiang, C.H.; Chang, F.Y.; Lee, S.D. Cytochrome P450 E1 genotype and the susceptibility to antituberculosis drug-induced hepatitis. Hepatology 2003, 37, 924–930. [Google Scholar]
- Vuilleumier, N.; Rossier, M.F.; Chiappe, A.; Degoumois, F.; Dayer, P.; Mermillod, B.; Nicod, L.; Desmeules, J.; Hochstrasser, D. CYP2E1 genotype and isoniazid-induced hepatotoxicity in patients treated for latent tuberculosis. Eur. J. Clin. Pharmacol 2006, 62, 423–429. [Google Scholar]
- Daly, A.K.; Aithal, G.P.; Leathart, J.B.; Swainsbury, R.A.; Dang, T.S.; Day, C.P. Genetic susceptibility to diclofenac-induced hepatotoxicity: contribution of UGT2B7, CYP2C8, and ABCC2 genotypes. Gastroenterology 2007, 132, 272–281. [Google Scholar]
- Metushi, I.G.; Cai, P.; Zhu, X.; Nakagawa, T.; Uetrecht, J.P. A fresh look at the mechanism of isoniazid-induced hepatotoxicity. Clin. Pharmacol. Ther 2011, 89, 911–914. [Google Scholar]
- Ueda, K.; Ishitsu, T.; Seo, T.; Ueda, N.; Murata, T.; Hori, M.; Nakagawa, K. Glutathione S-transferase M1 null genotype as a risk factor for carbamazepine-induced mild hepatotoxicity. Pharmacogenomics 2007, 8, 435–442. [Google Scholar]
- Huang, Y.S. Genetic polymorphisms of drug-metabolizing enzymes and the susceptibility to antituberculosis drug-induced liver injury. Expert Opin. Drug Metab. Toxicol 2007, 3, 1–8. [Google Scholar]
- Leiro, V.; Fernandez-Villar, A.; Valverde, D.; Constenla, L.; Vazquez, R.; Pineiro, L.; Gonzalez-Quintela, A. Influence of glutathione S-transferase M1 and T1 homozygous null mutations on the risk of antituberculosis drug-induced hepatotoxicity in a Caucasian population. Liver Int 2008, 28, 835–839. [Google Scholar]
- Watanabe, I.; Tomita, A.; Shimizu, M.; Sugawara, M.; Yasumo, H.; Koishi, R.; Takahashi, T.; Miyoshi, K.; Nakamura, K.; Izumi, T.; et al. A study to survey susceptible genetic factors responsible for troglitazone-associated hepatotoxicity in Japanese patients with type 2 diabetes mellitus. Clin. Pharmacol. Ther 2003, 73, 435–455. [Google Scholar]
- Aithal, G.P.; Ramsay, L.; Daly, A.K.; Sonchit, N.; Leathart, J.B.; Alexander, G.; Kenna, J.G.; Caldwell, J.; Day, C.P. Hepatic adducts, circulating antibodies, and cytokine polymorphisms in patients with diclofenac hepatotoxicity. Hepatology 2004, 39, 1430–1440. [Google Scholar]
- Carr, D.F.; Alfirevic, A.; Tugwood, J.D.; Barratt, B.J.; Sherwood, J.; Smith, J.; Pirmohamed, M.; Park, B.K. Molecular and genetic association of interleukin-6 in tacrine-induced hepatotoxicity. Pharmacogenet. Genomics 2007, 17, 961–972. [Google Scholar]
- Njoku, D.B.; Talor, M.V.; Fairweather, D.; Frisancho-Kiss, S.; Odumade, O.A.; Rose, N.R. A novel model of drug hapten-induced hepatitis with increased mast cells in the BALB/c mouse. Exp. Mol. Pathol 2005, 78, 87–100. [Google Scholar]
- Njoku, D.B.; Li, Z.; Washington, N.D.; Mellerson, J.L.; Talor, M.V.; Sharma, R.; Rose, N.R. Suppressive and pro-inflammatory roles for IL-4 in the pathogenesis of experimental drug-induced liver injury. Eur. J. Immunol 2009, 39, 1652–1663. [Google Scholar]
- Njoku, D.B.; Mellerson, J.L.; Talor, M.V.; Kerr, D.R.; Faraday, N.R.; Outschoorn, I.; Rose, N.R. Role of CYP2E1 immunoglobulin G4 subclass antibodies and complement in pathogenesis of idiosyncratic drug-induced hepatitis. Clin. Vaccine Immunol 2006, 13, 258–265. [Google Scholar]
- Anderson, J.S.; Rose, N.R.; Martin, J.L.; Eger, E.I.; Njoku, D.B. Desflurane hepatitis associated with hapten and autoantigen-specific IgG4 antibodies. Anesth. Analg 2007, 104, 1452–1453. [Google Scholar]
- Nguyen, C.; Rose, N.R.; Njoku, D.B. Trifluoroacetylated IgG4 antibodies in a child with idiosyncratic acute liver failure after first exposure to halothane. J. Pediatr. Gastroenterol. Nutr 2008, 47, 199–202. [Google Scholar]
- Higuchi, S.; Kobayashi, M.; Yoshikawa, Y.; Tsuneyama, K.; Fukami, T.; Nakajima, M.; Yokoi, T. IL-4 mediates dicloxacillin-induced liver injury in mice. Toxicol. Lett 2011, 200, 139–145. [Google Scholar]
- Cho, J.; Kim, L.; Li, Z.; Rose, N.R.; Talor, M.V.; Njoku, D.B. Sex bias in experimental immune-mediated, drug-induced liver injury in BALB/c mice: suggested roles for Tregs, estrogen, and IL-6. PLoS One 2013, 8, e61186. [Google Scholar]
- Connolly, M.K.; Ayo, D.; Malhotra, A.; Hackman, M.; Bedrosian, A.S.; Ibrahim, J.; Cieza-Rubio, N.E.; Nguyen, A.H.; Henning, J.R.; Dorvil-Castro, M.; et al. Dendritic cell depletion exacerbates acetaminophen hepatotoxicity. Hepatology 2011, 54, 959–968. [Google Scholar]
- Masubuchi, Y.; Bourdi, M.; Reilly, T.P.; Graf, M.L.; George, J.W.; Pohl, L.R. Role of interleukin-6 in hepatic heat shock protein expression and protection against acetaminophen-induced liver disease. Biochem. Biophys. Res. Commun 2003, 304, 207–212. [Google Scholar]
- Bourdi, M.; Eiras, D.P.; Holt, M.P.; Webster, M.R.; Reilly, T.P.; Welch, K.D.; Pohl, L.R. Role of IL-6 in an IL-10 and IL-4 double knockout mouse model uniquely susceptible to acetaminophen-induced liver injury. Chem. Res. Toxicol 2007, 20, 208–216. [Google Scholar]
- Masubuchi, Y.; Sugiyama, S.; Horie, T. Th1/Th2 cytokine balance as a determinant of acetaminophen-induced liver injury. Chem. Biol. Interact 2009, 179, 273–279. [Google Scholar]
- Jaeschke, H. Interleukin-4 and acetaminophen hepatotoxicity: a story of conflicting results and conclusions. Inflamm. Res 2014, 63, 171–172. [Google Scholar]
- Pires, D.A.; Marques, P.E.; Pereira, R.V.; David, B.A.; Gomides, L.F.; Dias, A.C.; Nunes-Silva, A.; Pinho, V.; Cara, D.C.; Vieira, L.Q.; et al. Interleukin-4 deficiency protects mice from acetaminophen-induced liver injury and inflammation by prevention of glutathione depletion. Inflamm. Res 2014, 63, 61–69. [Google Scholar]
- Ryan, P.M.; Bourdi, M.; Korrapati, M.C.; Proctor, W.R.; Vasquez, R.A.; Yee, S.B.; Quinn, T.D.; Chakraborty, M.; Pohl, L.R. Endogenous interleukin-4 regulates glutathione synthesis following acetaminophen-induced liver injury in mice. Chem. Res. Toxicol 2012, 25, 83–93. [Google Scholar]
- Yee, S.B.; Bourdi, M.; Masson, M.J.; Pohl, L.R. Hepatoprotective role of endogenous interleukin-13 in a murine model of acetaminophen-induced liver disease. Chem. Res. Toxicol 2007, 20, 734–744. [Google Scholar]
- Li, J.; Zhu, X.; Liu, F.; Cai, P.; Sanders, C.; Lee, W.M.; Uetrecht, J. Cytokine and autoantibody patterns in acute liver failure. J. Immunotoxicol 2010, 7, 157–164. [Google Scholar]
- Zhu, X.; Uetrecht, J. A novel T(H)17-type cell is rapidly increased in the liver in response to acetaminophen-induced liver injury: T(H)17 cells and the innate immune response. J. Immunotoxicol 2013, 10, 287–291. [Google Scholar]
- Yano, A.; Higuchi, S.; Tsuneyama, K.; Fukami, T.; Nakajima, M.; Yokoi, T. Involvement of immune-related factors in diclofenac-induced acute liver injury in mice. Toxicology 2012, 293, 107–114. [Google Scholar]
- Cua, D.J.; Tato, C.M. Innate IL-17-producing cells: the sentinels of the immune system. Nat. Rev. Immunol 2010, 10, 479–489. [Google Scholar]
- Jaeschke, H. Role of inflammation in the mechanism of acetaminophen-induced hepatotoxicity. Expert Opin. Drug Metab. Toxicol 2005, 1, 389–397. [Google Scholar]
- Ramaiah, S.K.; Jaeschke, H. Role of neutrophils in the pathogenesis of acute inflammatory liver injury. Toxicol. Pathol 2007, 35, 757–766. [Google Scholar]
- You, Q.; Cheng, L.; Reilly, T.P.; Wegmann, D.; Ju, C. Role of neutrophils in a mouse model of halothane-induced liver injury. Hepatology 2006, 44, 1421–1431. [Google Scholar]
- Proctor, W.R.; Chakraborty, M.; Chea, L.S.; Morrison, J.C.; Berkson, J.D.; Semple, K.; Bourdi, M.; Pohl, L.R. Eosinophils mediate the pathogenesis of halothane-induced liver injury in mice. Hepatology 2013, 57, 2026–2036. [Google Scholar]
- Furst, S.M.; Luedke, D.; Gandolfi, A.J. Kupffer cells from halothane-exposed guinea pigs carry trifluoroacetylated protein adducts. Toxicology 1997, 120, 119–132. [Google Scholar]
- Cheng, L.; You, Q.; Yin, H.; Holt, M.; Franklin, C.; Ju, C. Effect of polyI:C cotreatment on halothane-induced liver injury in mice. Hepatology 2009, 49, 215–226. [Google Scholar]
- Ju, C.; Reilly, T.P.; Bourdi, M.; Radonovich, M.F.; Brady, J.N.; George, J.W.; Pohl, L.R. Protective role of Kupffer cells in acetaminophen-induced hepatic injury in mice. Chem. Res. Toxicol 2002, 15, 1504–1513. [Google Scholar]
- You, Q.; Holt, M.; Yin, H.; Li, G.; Hu, C.J.; Ju, C. Role of hepatic resident and infiltrating macrophages in liver repair after acute injury. Biochem. Pharmacol 2013, 86, 836–843. [Google Scholar]
- Fisher, J.E.; McKenzie, T.J.; Lillegard, J.B.; Yu, Y.; Juskewitch, J.E.; Nedredal, G.I.; Brunn, G.J.; Yi, E.S.; Malhi, H.; Smyrk, T.C.; et al. Role of Kupffer cells and toll-like receptor 4 in acetaminophen-induced acute liver failure. J. Surg. Res 2013, 180, 147–155. [Google Scholar]
- Gressner, O.A.; Lahme, B.; Koch, M.; Gressner, A.M. Evaluation of hepatotropic targeting properties of allogenic and xenogenic erythrocyte ghosts in normal and liver-injured rats. Liver Int 2008, 28, 220–232. [Google Scholar]
- Gardner, C.R.; Hankey, P.; Mishin, V.; Francis, M.; Yu, S.; Laskin, J.D.; Laskin, D.L. Regulation of alternative macrophage activation in the liver following acetaminophen intoxication by stem cell-derived tyrosine kinase. Toxicol. Appl. Pharmacol 2012, 262, 139–148. [Google Scholar]
- Correll, P.H.; Iwama, A.; Tondat, S.; Mayrhofer, G.; Suda, T.; Bernstein, A. Deregulated inflammatory response in mice lacking the STK/RON receptor tyrosine kinase. Genes Funct 1997, 1, 69–83. [Google Scholar]
- Saiman, Y.; Friedman, S.L. The role of chemokines in acute liver injury. Front. Physiol 2012, 3, 213. [Google Scholar]
- Njoku, D.B.; Li, Z.; Mellerson, J.L.; Sharma, R.; Talor, M.V.; Barat, N.; Rose, N.R. IP-10 protects while MIP-2 promotes experimental anesthetic hapten-induced hepatitis. J. Autoimmun 2009, 32, 52–59. [Google Scholar]
Subject of study | Significant CYP gene |
---|---|
Warfarin dose requirement | CYP2C9 and CYP4F2a |
Acenocoumarol dose requirement | CYP2C9 and CYP4F2a |
Response to clopidogrel | CYP2C19 |
Smoking behavior | CYP2A6b |
Caffeine intake | CYP1A2c |
Gene | Common variant alleles | Functional effect |
---|---|---|
CYP1A2 | CYP1A2*1F | High induced activity |
CYP2A6 | CYP2A6*2 and *4 | Absence of activity |
CYP2A6*1X2A and *1X2B | High activity | |
CYP2B6 | CYP2B6*2, *5 and *6 | ?Decreased activity |
CYP2C8 | CYP2C8*2, *3 and *4 | ?Decreased activity |
CYP2C8*5 | Absence of activity | |
CYP2C9 | CYP2C9*2 and *3 | Low activity |
CYP2C9*6 | No activity | |
CYP2C19 | CYP2C19*2 and *3 | No activity |
CYP2C19*17 | High activity | |
CYP2D6 | CYP2D6*3, *4, *5 and *6 | No activity |
CYP2D6*10 and *17 | Low activity | |
CYP2D6*1XN and *2XN | High activity | |
CYP3A5 | CYP3A5*3 | No expression |
© 2014 by the authors; licensee MDPI, Basel, Switzerland This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).
Share and Cite
Njoku, D.B. Drug-Induced Hepatotoxicity: Metabolic, Genetic and Immunological Basis. Int. J. Mol. Sci. 2014, 15, 6990-7003. https://doi.org/10.3390/ijms15046990
Njoku DB. Drug-Induced Hepatotoxicity: Metabolic, Genetic and Immunological Basis. International Journal of Molecular Sciences. 2014; 15(4):6990-7003. https://doi.org/10.3390/ijms15046990
Chicago/Turabian StyleNjoku, Dolores B. 2014. "Drug-Induced Hepatotoxicity: Metabolic, Genetic and Immunological Basis" International Journal of Molecular Sciences 15, no. 4: 6990-7003. https://doi.org/10.3390/ijms15046990